ReviewAmerican journal of translational research2026
Serum alpha-fetoprotein kinetics as a mechanistic biomarker for rAAV-TK/GCV efficacy in hepatocellular carcinoma.
Review in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) remains a major fatal disease, and recombinant adeno-associated virus-thymidine kinase/ganciclovir (rAAV-tk/GCV) therapy is a newly discovered gene therapy with a unique mechanism of action for HCC. In the context of rAAV-tk/GCV treatment, serum alpha-fetoprotein (AFP), a commonly used clinical marker, is more of a static tumor-positive/negative biomarker and cannot dynamically and comprehensively reflect the pharmacodynamic response. Therefore, this article constructed a mechanistic model and integrates clinical and preclinical research data, proposing that changes in AFP kinetics are the result of four interacting processes: preferential elimination of proliferative tumor clones expressing high levels of AFP, heterogeneity of rAAV-tk transduction and the bystander effect of tk/GCV, treatment-induced liver tissue damage and regeneration in cirrhosis, and adaptive and innate immune responses. This article summarizes the typical AFP kinetics, including biphasic or uniphasic decline, lag phase, transient "rebound rise", low-level plateau phase, and secondary rise, and explains these characteristics in conjunction with reasonable physiologic mechanisms. Sources of uncertainty include impaired AFP clearance function or the basic regenerative state of the liver. Based on this, the article explores how early AFP kinetic parameters (e.g., percentage decline, slope, time to and depth of nadir) can serve as dynamic efficacy indicators and predictive biomarkers to facilitate dosage selection, trial enrichment and adaptive treatment. Finally, this article clarifies the main directions for translational research, including conducting follow-up clinical trials with intensive AFP sample collection, combining imaging detection and multi-omics analysis, and constructing of model-based decision-making models. It also proposes that the rational application of AFP kinetics based on its mechanism of action holds promise for significantly improving the optimization and clinical acceptance of rAAV-tk/GCV therapy in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.